Search

Displaying results 141 - 150 of 450 in total
  1. Drug

    Pirfenidone

    go.drugbank.com/drugs/DB04951
    ApprovedInvestigational

    Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneum...

  2. Drug

    Imatinib

    go.drugbank.com/drugs/DB00619
    ApprovedInvestigational

    [L42220] Imatinib was approved on February 1st ,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751]

  3. Drug

    Linvoseltamab

    go.drugbank.com/drugs/DB17447
    ApprovedInvestigational

    [L53353] It received conditional marketing authorization in the European Union in April 2025 for patients with three or more prior lines of therapy, [L53358] and was granted accelerated approval by the

  4. Drug

    Halofantrine

    go.drugbank.com/drugs/DB01218
    ApprovedWithdrawn

    Halofantrine has been shown to preferentially block open and inactivated HERG channels leading to some degree of cardiotoxicity.

  5. Drug

    ETBX-011

    go.drugbank.com/drugs/DB17464
    Investigational

    ETBX-011 is a cancer vaccine used to treat patients with cancers that express carcinoembryonic antigen (CEA).

  6. Drug

    Tecovirimat

    go.drugbank.com/drugs/DB12020
    ApprovedInvestigational

    [L3626, L3614] Tecovirimat was later approved by Health Canada in December 2021,[L39397] followed by the approval from the European Commission in January 2022.

  7. Drug

    Quinestrol

    go.drugbank.com/drugs/DB04575
    Approved

    The 3-cyclopentyl ether of ethinyl estradiol.

  8. Drug

    MB-102 CD123 CAR

    go.drugbank.com/drugs/DB17366
    Investigational

    MB-102 are autologous T cells genetically modified to express CD123-specific, hinge-optimized CD28-costimulatory chimeric receptor and a truncated human epidermal growth factor receptor.

  9. Drug

    Ciltacabtagene autoleucel

    go.drugbank.com/drugs/DB16738
    ApprovedInvestigational

    [A245854] While normally expressed on plasma blasts and plasma cells, BCMA is widely expressed on malignant plasma cells and most multiple myeloma cell lines, making it a choice target in the development … [L40739] Re-infusion of these modified T-cells leads to the targeted elimination of malignant plasma cells, on which BCMA is highly expressed.

  10. Drug

    Triflusal

    go.drugbank.com/drugs/DB08814
    ApprovedWithdrawn

    Triflusal is a 2-acetoxy-4-trifluoromethylbenzoic acid and it is an aspirin chemically-related molecule but not a derivative. The benefits of this agent are the lack of action over the arachidonic acid pathway, the driven production of n...